The Guilty Gilt Guide was written with a clear objective – to maximize the whole-herd performance of pig populations by helping gilts to reach their full reproductive potential and produce healthy pigs that reach their full genetic potential during grow-finish.
The open reading frames (ORF)5 represents approximately 4% of the porcine repro- ductive and respiratory syndrome virus (PRRSV)-2 genome (whole-PRRSV) and is often determined by the Sanger technique, which rarely detects >1 PRRSV strain if present in the sample.
Porcine reproductive and respiratory syndrome virus (PRRSV) is an important swine pathogen affecting the global swine industry.
Mycoplasma hyopneumoniae (M. hyopneumoniae) infections continue to result in significant respiratory challenges in the swine industry worldwide. Vaccination for M. hyopneumoniae is commonly utilized, as reduction in bacterial loads and clinical severity in vaccinated pigs have been shown. However, the effect of M. hyopneumoniae vaccination on transmission across different pig populations has been minimally investigated.
Don’t miss any news on PRRS disease control Subscribe now to PRRS.com newsletter
In conclusion, this summary confirms the ability of a modified live PRRS vaccine (Ingelvac® PRRS MLV) to provide heterologous protection following virulent challenge with the European LV strain of PRRS.
The use of Ingelvac PRRS® vaccines can significantly reduce lung lesions following challenge with heterologous isolates (86-94% ORF5 nucleotide similarity) in the three-week-old pig respiratory challenge model. However, the efficacy of Ingelvac PRRS® MLV vaccine against current virulent PRRSV isolates, such as RFLP 1-7-4, has not been reported to date.
Impact of a modified-live porcine reproductive and respiratory syndrome virus vaccine intervention on a population of pigs infected with a heterologous isolate
A single dose of the Ingelvac® PRRS modified live vaccine significantly reduced piglet loss after both heterologous European virus challenges.